常茂生物中期报告 2024

目錄 2 26 1 HH 1228213034 2 34 2.1 3 4 5 8 950,210,000903,495,000 9 10 15%25% 11 18,786,0004,157,000529,700,000529,700,000 12 13 14 (a) 2,500,000343,500,000183,700,000HHHH 70,468,00071,222,000 4.3%4.4%3.2%3.4% 21 22 313,802,000296,608,0005.8%18,786,0004,157,000 12 5.8% (1) (2) (1) (2) (3) (4) 29%26%71%74% 532,729,000492,613,00019 48,492,00086,586,000 1950.1%47.6%62,029,00089,554,000 64757442,389,00036,502,00040,000,000 (a)5% (b)5%(c)5% 22 XV(a)XV78(b)352(c)C3(d)622 (a)96,500A135,000,000170,000A100,000B70%2,500,00012,184,000H52,000H(b) (b)73,500A53,000B135,000,000170,000A100,000B30%2,500,00052,000H12,184,000H(a) (c)2,000B135,000,000170,000A100,000B200,00067,500,0006,750,000 (d)380,00067,500,0006,750,0002,000B135,000,000170,000A100,000B (e)66,000,0002,620,000H (f)220,00067,500,0006,750,000 權益披露 (g)800B135,000,000170,000A100,000B120,00067,500,0006,750,000 (h)2,500,000 (i)343,500,000 (j)183,700,000H XV(a)XV78(b)352(c)C3(d)622 XV23 XV23336 (a)66,000,0002,620,000H (b)100%62,500,000 (c)62.3%100%62,500,000 XV23336 529,700,000 (a)0.10 (b)0.10 (c)0.10 H H (a) (b) (c) (d) C1 詞彙 H